WallStSmart

Cosmos Health Inc. (COSM)vsHenry Schein Inc (HSIC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 18349% more annual revenue ($13.60B vs $73.73M). HSIC leads profitability with a 3.0% profit margin vs -33.1%. HSIC earns a higher WallStSmart Score of 56/100 (C).

COSM

Hold

36

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -2.45

HSIC

Buy

56

out of 100

Grade: C

Growth: 6.0Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: 2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COSM.

HSICUndervalued (+47.6%)

Margin of Safety

+47.6%

Fair Value

$156.00

Current Price

$86.37

$69.63 discount

UndervaluedFair: $156.00Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COSM2 strengths · Avg: 9.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
28.8%8/10

Revenue surging 28.8% year-over-year

HSIC0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

COSM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$40.92M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-106.6%2/10

ROE of -106.6% — below average capital efficiency

Free Cash FlowQuality
$-1.78M2/10

Negative free cash flow — burning cash

HSIC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.694/10

Expensive relative to growth rate

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.213/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : COSM

The strongest argument for COSM centers on Price/Book, Revenue Growth. Revenue growth of 28.8% demonstrates continued momentum.

Bull Case : HSIC

HSIC has a balanced fundamental profile.

Bear Case : COSM

The primary concerns for COSM are EPS Growth, Market Cap, Return on Equity.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, Profit Margin, Debt/Equity. Thin 3.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

COSM profiles as a growth stock while HSIC is a value play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.17 — expect wider price swings.

COSM is growing revenue faster at 28.8% — sustainability is the question.

HSIC generates stronger free cash flow (196M), providing more financial flexibility.

Bottom Line

HSIC scores higher overall (56/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?